The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline (GSK) to bring you the latest research news quickly.

[PRESS RELEASE]

GSK Announces Availability of Authorized Generic ADVAIR DISKUS® (fluticasone propionate/salmeterol inhalation powder)

GSK announced today plans to make available an authorized generic (AG) of ADVAIR DISKUS (fluticasone propionate/salmeterol inhalation powder) in all three approved strengths. The authorized generic will be manufactured by GSK and distributed by Prasco LLC. The authorized generic contains the same medicines in the same DISKUS device familiar to patients with the same instructions for use as ADVAIR DISKUS.

We recognize that generic medicines are an important part of the lifecycle of a medicine. GSK supports the availability of high quality generic drugs that have met regulatory requirements, and in which the public can have confidence after the branded product loses exclusivity.

Our goal is to ensure that patients continue to have access to the medicines in ADVAIR, in the DISKUS device that is familiar to them either in branded or generic form.

Click here for ADVAIR DISKUS prescribing information.

Please contact the GSK Response Center at 888-825-5249 or contact us online with any questions regarding ADVAIR DISKUS.